Drug intelligence / Profile preview

FA-DOX-Ng

Development stage: Preclinical
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Intravenous

Overview

**FA-DOX-Ng** is an experimental folate receptor-targeted, doxorubicin-loaded chitosan nanogel developed as a pH-responsive nanomedicine for colorectal cancer. Folic-acid surface targeting is intended to enhance folate receptor-mediated uptake by tumor cells, while the chitosan nanogel carrier releases doxorubicin preferentially in acidic tumor-associated conditions. In HT-29 colorectal cancer cells, the formulation increased doxorubicin cytotoxicity and induced apoptosis, with reported modulation of PTEN, AKT, BAX, BCL2, and caspase-associated apoptotic signaling. It is a preclinical delivery formulation rather than an approved pharmaceutical product.

Other names: folate-conjugated doxorubicin-loaded chitosan nanogel

Targets

DNATOP2A (DNA topoisomerase II)FOLR1 (FRα)

Beyond the preview

Go deeper on FA-DOX-Ng.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FA-DOX-Ng.